Associated Papers
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.
Chrisochoidou Y et al.
Blood, 2025
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders.
Hanzl A et al.
Nature Chemical Biology, 2023
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
34516913 (PubMed )
Supplement: sciadv.abi6856_tables_s1_to_s8.zip › sciadv.abi6856_Table_S4.xlsx › Sheet1
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.
Barrio S et al.
Haematologica, 2020
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM et al.
Blood, 2016
Select a paper to view details